Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

by · The Markets Daily

Equities research analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

TTNP stock opened at $5.00 on Tuesday. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80. The firm has a 50-day simple moving average of $5.80 and a 200-day simple moving average of $6.23.

Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.

Titan Pharmaceuticals Company Profile

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

Featured Articles